Global Wound Care Biologics Market - 2022-2029

Global Wound Care Biologics Market - 2022-2029:

Market Overview

Wound care biologics market size was valued at US$ xx million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 6.2% during the forecast period (2022-2029).

Wound care biologic therapies promote the re-establishment of the intrinsic repair mechanisms and application of these active biological agents, including plant-derived active biomolecules, which exhibit antimicrobial, antioxidant, or anti-inflammatory attributes. Biologic dressings help to prevent evaporative heat loss, water loss, protein and electrolyte loss, and contamination.

Market Dynamics

The wound care biologics market growth is driven by the rise in the incidence of burn injuries, the rising adoption of wound care biologics for treating injuries, the increase in the geriatric population, and research and development activities.

The rising prevalence of diabetes diseases is expected to drive the market growth

The rising incidence of diseases, such as diabetes and burn injuries, is expected to boost the market over the forecast period. As per the article published in Star Pearls in May 2022, the annual incidence of diabetic foot ulcers worldwide is between 9.1 to 26.1 million. Around 15 to 25% of patients with diabetes mellitus will develop a diabetic foot ulcer in their lifetime. As the number of newly diagnosed diabetics is increasing annually, the incidence of a diabetic foot ulcers is also bound to rise. Diabetic foot ulcers can arise at any age despite being most prevalent in ages 45 and over in patients with diabetes mellitus. Patients suffering from diabetes mellitus develop intense atherosclerosis of the small blood vessels in the legs and feet, directing to vascular compromise, which is another cause of diabetic foot infections. Healing is delayed, eventually leading to necrosis and gangrene because blood cannot reach the wound. The rising disease incidence leads to increasing demand for wound care biologics worldwide.

In addition, the market players are adopting different strategies, such as collaboration and product launches. For instance, in January 2021, Integra Lifesciences acquired ACell, Inc. This acquisition enabled Integra to deliver more comprehensive and complex wound management solutions.

The high cost of wound care will hamper the growth of the market

However, healthcare cost predictions for all wounds ranged from $28.2 to $96.7 billion, including costs for infection management, in which surgical wounds and diabetic ulcers were the most expensive to treat. Moreover, outpatient costs ($9.8–$35.7 billion) are higher than inpatient costs ($5.0–$24.3 billion), possibly due to increased outpatient wound treatments. These factors are limiting the market growth.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global wound care biologics market. Mainly, healthcare professionals treat chronic wounds at least once a week to assess the progress of the wound, provide debridement or apply CTPs (skin substitutes). The hospital outpatient department wound clinics had the primary care site to treat these wounds. Still, with the closing of many of these facilities during the initial COVID-19 rise, many patients with chronic wounds were not seen or delaying treatment.. This negatively affected the wound care market.

Some market players have faced difficulties developing new treatments because of the delay or cancellation of ongoing clinical trials and government restrictions to shut down the industries or to move the focus on managing the coronavirus infection.

In addition, the market players were engaged in expanding the business by adopting the market strategies such as acquisition or new product launches. Also, in November 2020, Stryker Corporation acquired Wright Medical Group N.V., a global medical devices company concentrated on extremities and biologics.

Segment Analysis

The chronic wounds segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The chronic wounds segment is expected to boost the market over the forecast period. Chronic wounds construct significant problems for patients. They are hurting and tender. Wounds often fatigue and emit odors, and involved dressings are often evident. Unprotected by an unbroken skin envelope, these wounds can be retraumatized and improvement in size. They may design an infection directed to sepsis and amputation. Patients with diabetes and obesity are at increased risk of developing chronic wounds. The vast majority of people who have a long open wound usually also have other significant health conditions. The simultaneous presence of a variety of chronic diseases is called comorbidity. Chronic wounds are usually confused by comorbidities, making it challenging to track chronic wounds as a disease.

As per the Wound Infection Clinical Practice data in 2022, the Standard clinical microbiology laboratory released outcomes that only supply information regarding a small subset of the bacterial species present, mainly in chronic wounds. If infection with fungi, mycobacteria or anaerobic bacteria is presumed, for example, following environmental contamination of a wound, this should be precisely requested or concerned with a microbiologist as these organisms need further examinations and processing. The increasing incidence and advanced diagnostics for chronic wounds drive the wound care biologic market.

Geographical Analysis

North America region holds the largest market share of the global Wound Care Biologics market

North America dominates the market for wound care biologics and is expected to show a similar trend over the forecast period. It is estimated to hold a significant market size over the forecast period (2022-2029) owing to the increasing geriatric population, technological advancement, and growing research and development activities. According to the article published in Advance in Wound Care in May 2021, chronic wounds are mostly seen in the elderly. In the United States, 3% of the population aged 65 has open wounds. By 2060, the U.S. government evaluates that the elderly population will be over 77 million, signifying that chronic wounds will resume being an increasingly constant concern in these people. Around the United States, 2% of the entire population is assessed to be impacted by chronic wounds.

In addition, the market players are applying market strategies such as collaboration and new product launches. For instance, in June 2021, MIMEDX received approval from the Japanese Ministry of Health, Labour and Welfare for the commercialization of Epifix in Japan. In April 2021, Kerecis presented its Kerecis Omega3 GraftGuide, an intact fish skin that uniquely manages the challenges of burn healing.

Competitive Landscape

The wound care biologics market is a moderately competitive presence of local and global companies. Some of the key players contributing to the market's growth are Organogenesis Inc., Integra Lifesciences, Smith and Nephew, Acell Inc., Osiris Therapeutics, Avita Medical, Solsys Medical, Generex Biotechnology, Mimedx, Skye Biologics among others. The major players are adopting several growth strategies, such as Treatment type launches, acquisitions, and collaborations, which are contributing to the growth of the wound care biologics market globally.

For instance,

• In July 2022, Biologics Company Tides Medical introduced Artacent AC, a tri-layer skin graft designed to treat complex or difficult-to-treat wounds.

• In May 2022, MIMEDX received USD 4.6 million in awards department of defense to evaluate PURION-processed Dehydrated Human Amnion Chorion Membrane (DHACM) to advance the treatment of combat casualty wounds and burns.

Zax Healthcare

Overview:

Organogenesis Inc. is a medicine company founded in 1985 and headquartered in the United States. The company offers a portfolio of acellular and bioactive biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine.

Product Portfolio:

PuraPly: It is an antimicrobial wound matrix is an FDA 510(k)-cleared Class II medical device used for the management of various types of wounds, including acute and chronic wound types, such as pressure ulcers, partial and full-thickness wounds, venous ulcers, chronic vascular ulcers, diabetic ulcers, tunneled/undermined wounds, draining wounds, trauma wounds, and first- and second-degree burns.

The global wound care biologics market report would provide access to approximately 65+ market data tables, 65+ figures, and in the range of 200+ (approximate) pages.